NTI to Launch Phase II Clinical Trial in Rett Syndrome
Filed with ASX · · 3 pages · English
Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, today announces the launch of a new clinical program in Rett Syndrome, comprising an upcoming filing for Human Research Ethics Committee (HREC) approval and thereafter, the commencement of a Phase II clinical t
Neurotech International Ltd. on 6ix
In the deck
Story so far
Earlier from Neurotech International
- Phase I/II ASD Clinical Trials Results at 52 Weeks
- First Patient Treated in Phase I/II PANDAS/PANS Trial
- Approval for Additional Phase I/II ASD Trial Extension
- HREC Approval for Phase I/II PANDAS/PANS Clinical Trial
- NTI Granted FDA Pre-IND Meeting for NTI164 in ASD
Later from Neurotech International
- NTI Completes Recruitment in PANDAS/PANS Clinical Trial
- NTI granted HREC Approval for PANDAS/PANS Trial Extension
- NTI Granted 2 Year Extension of Treatment for ASD Patients
- NTI Receives HREC Approval for Rett Syndrome Clinical Trial
- First Patient Treated in Rett Syndrome Clinical Trial
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International